Cure My Disease

Don't miss your cure!

 Log in / Sign up

Brain scan may replace biopsy for tumor grading

NCT ID NCT07813741

Diagnosis Sponsor: Assiut University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 10, 2026 · Last updated Sep 11, 2026 · Updated 1 time

Summary

Gliomas are the most common primary brain tumors in adults, and knowing whether a tumor is low-grade or high-grade before surgery guides treatment and prognosis. Currently, doctors need a tissue sample from surgery or biopsy to grade a glioma, and standard MRI scans often cannot tell the difference reliably. This study tests whether an advanced MRI technique called susceptibility-weighted imaging (SWI) can grade gliomas non-invasively by detecting tiny blood vessel changes and microbleeds that are more common in high-grade tumors. About 90 adults with suspected gliomas will receive a preoperative brain MRI that includes SWI, and two radiologists will grade the images without knowing the pathology results. Researchers will then compare the imaging grades against the final tissue diagnosis to measure how accurate SWI is.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
susceptibility-weighted imaging (SWI), an advanced MRI scan
What this could lead to
If SWI proves accurate, doctors could grade gliomas before surgery without a tissue sample, helping plan operations and treatment sooner.
What could go wrong
This is a small observational study at one center. SWI may not match pathology results closely enough, and findings might not hold in other hospitals or MRI machines.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 90 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Oct 2026

An estimate. Start dates often move.

Expected to finish

Nov 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Adult patients presenting to Assiut University Hospital with radiologically suspected cerebral gliomas on initial neuroimaging (CT or MRI) who are referred to the Department of Diagnostic and Interventional Radiology in collaboration with the Department of Neurosurgery, and scheduled for subsequent surgical resection or stereotactic biopsy.

Ages

18 years and older

Sex

Anyone

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adult patients aged 18 years and older. * Neuroimaging (CT or MRI) findings suggestive of cerebral glioma. * Patients scheduled for surgical resection or stereotactic biopsy. Exclusion Criteria: * Previous brain surgery for the same lesion. * Previous cranial radiotherapy or chemotherapy. * General contraindications to MRI (e.g., cardiac pacemakers, ferromagnetic implants, or severe claustrophobia). * Poor-quality MRI examinations compromised by significant motion or susceptibility artifacts.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Brain neoplasms are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

brain cancer brain glioma brain neoplasm glioma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Brain neoplasms Cerebral glioma GLIOMA

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    The full official record for this study. This one lists no contact details, but it is the first place any would appear.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.